ID   AFG32_HUMAN             Reviewed;         797 AA.
AC   Q9Y4W6; Q6P1L0;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   29-SEP-2021, entry version 202.
DE   RecName: Full=AFG3-like protein 2 {ECO:0000305};
DE            EC=3.4.24.- {ECO:0000269|PubMed:14623864, ECO:0000269|PubMed:22354088};
DE   AltName: Full=Paraplegin-like protein;
DE   Flags: Precursor;
GN   Name=AFG3L2 {ECO:0000312|HGNC:HGNC:315};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RX   PubMed=10395799; DOI=10.1006/geno.1999.5818;
RA   Banfi S., Bassi M.T., Andolfi G., Marchitiello A., Zanotta S., Ballabio A.,
RA   Casari G., Franco B.;
RT   "Identification and characterization of AFG3L2, a novel paraplegin-related
RT   gene.";
RL   Genomics 59:51-58(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   INTERACTION WITH SPG7.
RX   PubMed=14623864; DOI=10.1083/jcb.200304112;
RA   Atorino L., Silvestri L., Koppen M., Cassina L., Ballabio A., Marconi R.,
RA   Langer T., Casari G.;
RT   "Loss of m-AAA protease in mitochondria causes complex I deficiency and
RT   increased sensitivity to oxidative stress in hereditary spastic
RT   paraplegia.";
RL   J. Cell Biol. 163:777-787(2003).
RN   [4]
RP   SUBUNIT.
RX   PubMed=17101804; DOI=10.1128/mcb.01470-06;
RA   Koppen M., Metodiev M.D., Casari G., Rugarli E.I., Langer T.;
RT   "Variable and tissue-specific subunit composition of mitochondrial m-AAA
RT   protease complexes linked to hereditary spastic paraplegia.";
RL   Mol. Cell. Biol. 27:758-767(2007).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=22354088; DOI=10.1038/embor.2012.14;
RA   Greene A.W., Grenier K., Aguileta M.A., Muise S., Farazifard R.,
RA   Haque M.E., McBride H.M., Park D.S., Fon E.A.;
RT   "Mitochondrial processing peptidase regulates PINK1 processing, import and
RT   Parkin recruitment.";
RL   EMBO Rep. 13:378-385(2012).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [8]
RP   INTERACTION WITH SPG7.
RX   PubMed=26387735; DOI=10.1016/j.molcel.2015.08.009;
RA   Shanmughapriya S., Rajan S., Hoffman N.E., Higgins A.M., Tomar D.,
RA   Nemani N., Hines K.J., Smith D.J., Eguchi A., Vallem S., Shaikh F.,
RA   Cheung M., Leonard N.J., Stolakis R.S., Wolfers M.P., Ibetti J.,
RA   Chuprun J.K., Jog N.R., Houser S.R., Koch W.J., Elrod J.W., Madesh M.;
RT   "SPG7 is an essential and conserved component of the mitochondrial
RT   permeability transition pore.";
RL   Mol. Cell 60:47-62(2015).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [10]
RP   INTERACTION WITH MAIP1.
RX   PubMed=27499296; DOI=10.1016/j.molcel.2016.06.033;
RA   Floyd B.J., Wilkerson E.M., Veling M.T., Minogue C.E., Xia C., Beebe E.T.,
RA   Wrobel R.L., Cho H., Kremer L.S., Alston C.L., Gromek K.A., Dolan B.K.,
RA   Ulbrich A., Stefely J.A., Bohl S.L., Werner K.M., Jochem A.,
RA   Westphall M.S., Rensvold J.W., Taylor R.W., Prokisch H., Kim J.J.,
RA   Coon J.J., Pagliarini D.J.;
RT   "Mitochondrial protein interaction mapping identifies regulators of
RT   respiratory chain function.";
RL   Mol. Cell 63:621-632(2016).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH MAIP1.
RX   PubMed=27642048; DOI=10.1016/j.molcel.2016.08.020;
RA   Koenig T., Troeder S.E., Bakka K., Korwitz A., Richter-Dennerlein R.,
RA   Lampe P.A., Patron M., Muehlmeister M., Guerrero-Castillo S., Brandt U.,
RA   Decker T., Lauria I., Paggio A., Rizzuto R., Rugarli E.I., De Stefani D.,
RA   Langer T.;
RT   "The m-AAA protease associated with neurodegeneration limits MCU activity
RT   in mitochondria.";
RL   Mol. Cell 64:148-162(2016).
RN   [12]
RP   STRUCTURE BY NMR OF 164-251.
RG   Northeast structural genomics consortium (NESG);
RT   "Northeast structural genomics consortium target HR6741A.";
RL   Submitted (MAR-2012) to the PDB data bank.
RN   [13]
RP   VARIANT SCA28 LYS-700.
RX   PubMed=20354562; DOI=10.1038/ejhg.2010.40;
RA   Edener U., Wollner J., Hehr U., Kohl Z., Schilling S., Kreuz F., Bauer P.,
RA   Bernard V., Gillessen-Kaesbach G., Zuhlke C.;
RT   "Early onset and slow progression of SCA28, a rare dominant ataxia in a
RT   large four-generation family with a novel AFG3L2 mutation.";
RL   Eur. J. Hum. Genet. 18:965-968(2010).
RN   [14]
RP   VARIANTS SCA28 ILE-654; VAL-666; ARG-666; THR-666; ARG-671 AND GLU-671.
RX   PubMed=20725928; DOI=10.1002/humu.21342;
RA   Cagnoli C., Stevanin G., Brussino A., Barberis M., Mancini C.,
RA   Margolis R.L., Holmes S.E., Nobili M., Forlani S., Padovan S., Pappi P.,
RA   Zaros C., Leber I., Ribai P., Pugliese L., Assalto C., Brice A., Migone N.,
RA   Durr A., Brusco A.;
RT   "Missense mutations in the AFG3L2 proteolytic domain account for
RT   approximately 1.5% of European autosomal dominant cerebellar ataxias.";
RL   Hum. Mutat. 31:1117-1124(2010).
RN   [15]
RP   VARIANTS SCA28 THR-432; LYS-691; GLU-694 AND GLN-702, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=20208537; DOI=10.1038/ng.544;
RA   Di Bella D., Lazzaro F., Brusco A., Plumari M., Battaglia G., Pastore A.,
RA   Finardi A., Cagnoli C., Tempia F., Frontali M., Veneziano L., Sacco T.,
RA   Boda E., Brussino A., Bonn F., Castellotti B., Baratta S., Mariotti C.,
RA   Gellera C., Fracasso V., Magri S., Langer T., Plevani P., Di Donato S.,
RA   Muzi-Falconi M., Taroni F.;
RT   "Mutations in the mitochondrial protease gene AFG3L2 cause dominant
RT   hereditary ataxia SCA28.";
RL   Nat. Genet. 42:313-321(2010).
RN   [16]
RP   VARIANT SPAX5 CYS-616, AND CHARACTERIZATION OF VARIANT SPAX5 CYS-616.
RX   PubMed=22022284; DOI=10.1371/journal.pgen.1002325;
RA   Pierson T.M., Adams D., Bonn F., Martinelli P., Cherukuri P.F., Teer J.K.,
RA   Hansen N.F., Cruz P., Mullikin J.C., Blakesley R.W., Golas G., Kwan J.,
RA   Sandler A., Fuentes Fajardo K., Markello T., Tifft C., Blackstone C.,
RA   Rugarli E.I., Langer T., Gahl W.A., Toro C.;
RT   "Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic
RT   ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases.";
RL   PLoS Genet. 7:E1002325-E1002325(2011).
RN   [17]
RP   VARIANT SCA28 HIS-689.
RX   PubMed=24293060; DOI=10.1007/s12031-013-0187-1;
RA   Loebbe A.M., Kang J.S., Hilker R., Hackstein H., Mueller U., Nolte D.;
RT   "A novel missense mutation in AFG3L2 associated with late onset and slow
RT   progression of spinocerebellar ataxia type 28.";
RL   J. Mol. Neurosci. 52:493-496(2014).
RN   [18]
RP   VARIANT SCA28 ASN-689.
RX   PubMed=26677414; DOI=10.1186/s40673-015-0038-7;
RA   Zuehlke C., Mikat B., Timmann D., Wieczorek D., Gillessen-Kaesbach G.,
RA   Buerk K.;
RT   "Spinocerebellar ataxia 28: a novel AFG3L2 mutation in a German family with
RT   young onset, slow progression and saccadic slowing.";
RL   Cerebellum Ataxias 2:19-19(2015).
RN   [19]
RP   VARIANT OPA12 CYS-468, AND INVOLVEMENT IN OPA12.
RX   PubMed=26539208; DOI=10.3389/fgene.2015.00311;
RA   Charif M., Roubertie A., Salime S., Mamouni S., Goizet C., Hamel C.P.,
RA   Lenaers G.;
RT   "A novel mutation of AFG3L2 might cause dominant optic atrophy in patients
RT   with mild intellectual disability.";
RL   Front. Genet. 6:311-311(2015).
RN   [20]
RP   VARIANT OPA12 CYS-468, AND INVOLVEMENT IN OPA12.
RX   PubMed=29181157; DOI=10.3892/br.2017.987;
RA   Colavito D., Maritan V., Suppiej A., Del Giudice E., Mazzarolo M.,
RA   Miotto S., Farina S., Dalle Carbonare M., Piermarocchi S., Leon A.;
RT   "Non-syndromic isolated dominant optic atrophy caused by the p.R468C
RT   mutation in the AFG3 like matrix AAA peptidase subunit 2 gene.";
RL   Biomed. Rep. 7:451-454(2017).
RN   [21]
RP   VARIANTS SCA28 VAL-621 AND VAL-666.
RX   PubMed=29053796; DOI=10.1093/brain/awx251;
RA   Nibbeling E.A.R., Duarri A., Verschuuren-Bemelmans C.C., Fokkens M.R.,
RA   Karjalainen J.M., Smeets C.J.L.M., de Boer-Bergsma J.J., van der Vries G.,
RA   Dooijes D., Bampi G.B., van Diemen C., Brunt E., Ippel E., Kremer B.,
RA   Vlak M., Adir N., Wijmenga C., van de Warrenburg B.P.C., Franke L.,
RA   Sinke R.J., Verbeek D.S.;
RT   "Exome sequencing and network analysis identifies shared mechanisms
RT   underlying spinocerebellar ataxia.";
RL   Brain 140:2860-2878(2017).
RN   [22]
RP   VARIANT OPA12 CYS-468, CHARACTERIZATION OF VARIANT OPA12 CYS-468,
RP   CHARACTERIZATION OF VARIANT SCA28 LYS-691, MUTAGENESIS OF GLU-575,
RP   FUNCTION, AND INTERACTION WITH SPG7.
RX   PubMed=30252181; DOI=10.1002/humu.23658;
RA   Magri S., Fracasso V., Plumari M., Alfei E., Ghezzi D., Gellera C.,
RA   Rusmini P., Poletti A., Di Bella D., Elia A.E., Pantaleoni C., Taroni F.;
RT   "Concurrent AFG3L2 and SPG7 mutations associated with syndromic
RT   parkinsonism and optic atrophy with aberrant OPA1 processing and
RT   mitochondrial network fragmentation.";
RL   Hum. Mutat. 39:2060-2071(2018).
RN   [23]
RP   VARIANT OPA12 GLU-337, CHARACTERIZATION OF VARIANT OPA12 GLU-337, AND
RP   FUNCTION.
RX   PubMed=32600459; DOI=10.1186/s40478-020-00975-w;
RA   Baderna V., Schultz J., Kearns L.S., Fahey M., Thompson B.A., Ruddle J.B.,
RA   Huq A., Maltecca F.;
RT   "A novel AFG3L2 mutation close to AAA domain leads to aberrant OMA1 and
RT   OPA1 processing in a family with optic atrophy.";
RL   Acta Neuropathol. Commun. 8:93-93(2020).
RN   [24]
RP   INVOLVEMENT IN OPA12, VARIANTS SPAX5 GLU-306; VAL-462 AND LYS-620, VARIANTS
RP   OPA12 PHE-346; SER-377; GLY-407; ILE-430; VAL-462; LYS-465; LEU-514 AND
RP   CYS-605, CHARACTERIZATION OF VARIANTS OPA12 GLY-407; VAL-462; LYS-465 AND
RP   LEU-514, AND CHARACTERIZATION OF VARIANT SPAX5 LYS-620.
RX   PubMed=32219868; DOI=10.1002/ana.25723;
RA   Caporali L., Magri S., Legati A., Del Dotto V., Tagliavini F.,
RA   Balistreri F., Nasca A., La Morgia C., Carbonelli M., Valentino M.L.,
RA   Lamantea E., Baratta S., Schoels L., Schuele R., Barboni P.,
RA   Cascavilla M.L., Maresca A., Capristo M., Ardissone A., Pareyson D.,
RA   Cammarata G., Melzi L., Zeviani M., Peverelli L., Lamperti C.,
RA   Marzoli S.B., Fang M., Synofzik M., Ghezzi D., Carelli V., Taroni F.;
RT   "ATPase domain AFG3L2 mutations alter OPA1 processing and cause optic
RT   neuropathy.";
RL   Ann. Neurol. 88:18-32(2020).
RN   [25]
RP   VARIANTS OPA12 ALA-74; ARG-337; GLU-337; LYS-376; SER-416; LEU-514 AND
RP   SER-644.
RX   PubMed=32548275; DOI=10.1212/nxg.0000000000000428;
RA   Charif M., Chevrollier A., Gueguen N., Bris C., Goudenege D.,
RA   Desquiret-Dumas V., Leruez S., Colin E., Meunier A., Vignal C., Smirnov V.,
RA   Defoort-Dhellemmes S., Drumare Bouvet I., Goizet C., Votruba M.,
RA   Jurkute N., Yu-Wai-Man P., Tagliavini F., Caporali L., La Morgia C.,
RA   Carelli V., Procaccio V., Zanlonghi X., Meunier I., Reynier P., Bonneau D.,
RA   Amati-Bonneau P., Lenaers G.;
RT   "Mutations in the m-AAA proteases AFG3L2 and SPG7 are causing isolated
RT   dominant optic atrophy.";
RL   Neurol. Genet. 6:e428-e428(2020).
CC   -!- FUNCTION: ATP-dependent protease which is essential for axonal and
CC       neuron development. In neurons, mediates degradation of SMDT1/EMRE
CC       before its assembly with the uniporter complex, limiting the
CC       availability of SMDT1/EMRE for MCU assembly and promoting efficient
CC       assembly of gatekeeper subunits with MCU (PubMed:27642048). Required
CC       for paraplegin (SPG7) maturation (PubMed:30252181). After its cleavage
CC       by mitochondrial-processing peptidase (MPP), it converts paraplegin
CC       into a proteolytically active mature form (By similarity). Required for
CC       the maturation of PINK1 into its 52kDa mature form after its cleavage
CC       by mitochondrial-processing peptidase (MPP) (PubMed:22354088,
CC       PubMed:30252181). Involved in the regulation of OMA1-dependent
CC       processing of OPA1 (PubMed:32600459, PubMed:30252181).
CC       {ECO:0000250|UniProtKB:Q8JZQ2, ECO:0000269|PubMed:22354088,
CC       ECO:0000269|PubMed:27642048, ECO:0000269|PubMed:30252181,
CC       ECO:0000269|PubMed:32600459}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:Q9WZ49};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q9WZ49};
CC   -!- SUBUNIT: Homooligomer. Forms heterooligomers with SPG7 and AFG3L1
CC       (PubMed:17101804). Interacts with SPG7; the interaction is required for
CC       the efficient assembly of mitochondrial complex I (PubMed:14623864,
CC       PubMed:26387735, PubMed:30252181). Interacts with AFG3L1 (By
CC       similarity). Interacts with MAIP1 (PubMed:27499296, PubMed:27642048).
CC       Interacts with DNAJC19 and PHB2 (By similarity).
CC       {ECO:0000250|UniProtKB:Q8JZQ2, ECO:0000269|PubMed:14623864,
CC       ECO:0000269|PubMed:17101804, ECO:0000269|PubMed:26387735,
CC       ECO:0000269|PubMed:27499296, ECO:0000269|PubMed:27642048,
CC       ECO:0000269|PubMed:30252181}.
CC   -!- INTERACTION:
CC       Q9Y4W6; P42858: HTT; NbExp=3; IntAct=EBI-358755, EBI-466029;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:10395799,
CC       ECO:0000269|PubMed:22354088}. Mitochondrion inner membrane
CC       {ECO:0000250|UniProtKB:Q8JZQ2}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed in the cerebellar
CC       Purkinje cells. {ECO:0000269|PubMed:20208537}.
CC   -!- PTM: Upon import into the mitochondrion, the N-terminal transit peptide
CC       is cleaved to generate an intermediate form which undergoes
CC       autocatalytic proteolytic processing to generate the proteolytically
CC       active mature form. {ECO:0000250|UniProtKB:Q8JZQ2,
CC       ECO:0000269|PubMed:30252181}.
CC   -!- DISEASE: Spinocerebellar ataxia 28 (SCA28) [MIM:610246]:
CC       Spinocerebellar ataxia is a clinically and genetically heterogeneous
CC       group of cerebellar disorders. Patients show progressive incoordination
CC       of gait and often poor coordination of hands, speech and eye movements,
CC       due to degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCA28 is an autosomal dominant cerebellar
CC       ataxia (ADCA) with a slow progressive course and no evidence of sensory
CC       involvement or cognitive impairment. {ECO:0000269|PubMed:20208537,
CC       ECO:0000269|PubMed:20354562, ECO:0000269|PubMed:20725928,
CC       ECO:0000269|PubMed:24293060, ECO:0000269|PubMed:26677414,
CC       ECO:0000269|PubMed:29053796, ECO:0000269|PubMed:30252181}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Spastic ataxia 5, autosomal recessive (SPAX5) [MIM:614487]: A
CC       neurodegenerative disorder characterized by early onset spasticity,
CC       peripheral neuropathy, ptosis, oculomotor apraxia, dystonia, cerebellar
CC       atrophy, and progressive myoclonic epilepsy.
CC       {ECO:0000269|PubMed:22022284, ECO:0000269|PubMed:32219868}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Optic atrophy 12 (OPA12) [MIM:618977]: An autosomal dominant
CC       disease characterized by progressive visual loss in association with
CC       optic atrophy. Atrophy of the optic disk indicates a deficiency in the
CC       number of nerve fibers which arise in the retina and converge to form
CC       the optic disk, optic nerve, optic chiasm and optic tracts. OPA12
CC       patients manifest slowly progressive visual impairment with onset
CC       usually in the first decade. Some patients may exhibit additional
CC       features including impaired intellectual development, dystonia,
CC       movement disorders, or ataxia. {ECO:0000269|PubMed:26539208,
CC       ECO:0000269|PubMed:29181157, ECO:0000269|PubMed:30252181,
CC       ECO:0000269|PubMed:32219868, ECO:0000269|PubMed:32548275,
CC       ECO:0000269|PubMed:32600459}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the AAA ATPase
CC       family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the peptidase M41
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y18314; CAB48398.1; -; mRNA.
DR   EMBL; BC065016; AAH65016.1; -; mRNA.
DR   CCDS; CCDS11859.1; -.
DR   RefSeq; NP_006787.2; NM_006796.2.
DR   PDB; 2LNA; NMR; -; A=164-251.
DR   PDB; 6NYY; EM; 3.00 A; A/B/C/D/E/F=272-797.
DR   PDBsum; 2LNA; -.
DR   PDBsum; 6NYY; -.
DR   BMRB; Q9Y4W6; -.
DR   SMR; Q9Y4W6; -.
DR   BioGRID; 116139; 237.
DR   CORUM; Q9Y4W6; -.
DR   IntAct; Q9Y4W6; 81.
DR   MINT; Q9Y4W6; -.
DR   STRING; 9606.ENSP00000269143; -.
DR   DrugBank; DB00171; ATP.
DR   MEROPS; M41.007; -.
DR   GlyGen; Q9Y4W6; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9Y4W6; -.
DR   MetOSite; Q9Y4W6; -.
DR   PhosphoSitePlus; Q9Y4W6; -.
DR   SwissPalm; Q9Y4W6; -.
DR   BioMuta; AFG3L2; -.
DR   DMDM; 126302516; -.
DR   EPD; Q9Y4W6; -.
DR   jPOST; Q9Y4W6; -.
DR   MassIVE; Q9Y4W6; -.
DR   MaxQB; Q9Y4W6; -.
DR   PaxDb; Q9Y4W6; -.
DR   PeptideAtlas; Q9Y4W6; -.
DR   PRIDE; Q9Y4W6; -.
DR   ProteomicsDB; 86254; -.
DR   TopDownProteomics; Q9Y4W6; -.
DR   Antibodypedia; 1387; 263 antibodies.
DR   DNASU; 10939; -.
DR   Ensembl; ENST00000269143; ENSP00000269143; ENSG00000141385.
DR   GeneID; 10939; -.
DR   KEGG; hsa:10939; -.
DR   UCSC; uc002kqz.3; human.
DR   CTD; 10939; -.
DR   DisGeNET; 10939; -.
DR   GeneCards; AFG3L2; -.
DR   GeneReviews; AFG3L2; -.
DR   HGNC; HGNC:315; AFG3L2.
DR   HPA; ENSG00000141385; Low tissue specificity.
DR   MalaCards; AFG3L2; -.
DR   MIM; 604581; gene.
DR   MIM; 610246; phenotype.
DR   MIM; 614487; phenotype.
DR   MIM; 618977; phenotype.
DR   neXtProt; NX_Q9Y4W6; -.
DR   OpenTargets; ENSG00000141385; -.
DR   Orphanet; 313772; Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome.
DR   Orphanet; 101109; Spinocerebellar ataxia type 28.
DR   PharmGKB; PA24612; -.
DR   VEuPathDB; HostDB:ENSG00000141385; -.
DR   eggNOG; KOG0731; Eukaryota.
DR   GeneTree; ENSGT00940000159566; -.
DR   HOGENOM; CLU_000688_23_1_1; -.
DR   InParanoid; Q9Y4W6; -.
DR   OMA; WQEFRNT; -.
DR   OrthoDB; 217929at2759; -.
DR   PhylomeDB; Q9Y4W6; -.
DR   TreeFam; TF105004; -.
DR   BRENDA; 3.4.24.B18; 2681.
DR   PathwayCommons; Q9Y4W6; -.
DR   Reactome; R-HSA-8949664; Processing of SMDT1.
DR   BioGRID-ORCS; 10939; 710 hits in 1035 CRISPR screens.
DR   ChiTaRS; AFG3L2; human.
DR   GeneWiki; AFG3L2; -.
DR   GenomeRNAi; 10939; -.
DR   Pharos; Q9Y4W6; Tbio.
DR   PRO; PR:Q9Y4W6; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; Q9Y4W6; protein.
DR   Bgee; ENSG00000141385; Expressed in primary visual cortex and 247 other tissues.
DR   ExpressionAtlas; Q9Y4W6; baseline and differential.
DR   Genevisible; Q9Y4W6; HS.
DR   GO; GO:0005745; C:m-AAA complex; IEA:Ensembl.
DR   GO; GO:0005743; C:mitochondrial inner membrane; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004176; F:ATP-dependent peptidase activity; IEA:InterPro.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008237; F:metallopeptidase activity; IMP:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:ProtInc.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007409; P:axonogenesis; IMP:UniProtKB.
DR   GO; GO:0036444; P:calcium import into the mitochondrion; IMP:UniProtKB.
DR   GO; GO:0042407; P:cristae formation; IBA:GO_Central.
DR   GO; GO:0033619; P:membrane protein proteolysis; IDA:UniProtKB.
DR   GO; GO:0051560; P:mitochondrial calcium ion homeostasis; IMP:UniProtKB.
DR   GO; GO:0008053; P:mitochondrial fusion; IBA:GO_Central.
DR   GO; GO:0034982; P:mitochondrial protein processing; IBA:GO_Central.
DR   GO; GO:0055001; P:muscle cell development; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0021675; P:nerve development; IEA:Ensembl.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   GO; GO:0016540; P:protein autoprocessing; ISS:UniProtKB.
DR   GO; GO:0016485; P:protein processing; ISS:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; IBA:GO_Central.
DR   GO; GO:0006508; P:proteolysis; IMP:UniProtKB.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0060013; P:righting reflex; IEA:Ensembl.
DR   Gene3D; 1.20.58.760; -; 1.
DR   Gene3D; 3.40.50.300; -; 1.
DR   HAMAP; MF_01458; FtsH; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR041569; AAA_lid_3.
DR   InterPro; IPR003959; ATPase_AAA_core.
DR   InterPro; IPR003960; ATPase_AAA_CS.
DR   InterPro; IPR005936; FtsH.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR011546; Pept_M41_FtsH_extracell.
DR   InterPro; IPR000642; Peptidase_M41.
DR   InterPro; IPR037219; Peptidase_M41-like.
DR   Pfam; PF00004; AAA; 1.
DR   Pfam; PF17862; AAA_lid_3; 1.
DR   Pfam; PF06480; FtsH_ext; 1.
DR   Pfam; PF01434; Peptidase_M41; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF140990; SSF140990; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR01241; FtsH_fam; 1.
DR   PROSITE; PS00674; AAA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Disease variant; Hydrolase; Membrane;
KW   Metal-binding; Metalloprotease; Mitochondrion;
KW   Mitochondrion inner membrane; Neurodegeneration; Nucleotide-binding;
KW   Protease; Reference proteome; Spinocerebellar ataxia; Transit peptide;
KW   Transmembrane; Transmembrane helix; Zinc.
FT   TRANSIT         1..38
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000250|UniProtKB:Q8JZQ2"
FT   PROPEP          39..66
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000250|UniProtKB:Q8JZQ2"
FT                   /id="PRO_0000442311"
FT   CHAIN           67..797
FT                   /note="AFG3-like protein 2"
FT                   /id="PRO_0000442312"
FT   TRANSMEM        143..163
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        251..271
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   NP_BIND         348..355
FT                   /note="ATP"
FT                   /evidence="ECO:0000255"
FT   REGION          76..126
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          759..797
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        84..102
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        771..797
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        575
FT                   /evidence="ECO:0000250|UniProtKB:Q9WZ49"
FT   METAL           574
FT                   /note="Zinc; catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WZ49"
FT   METAL           578
FT                   /note="Zinc; catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WZ49"
FT   METAL           649
FT                   /note="Zinc; catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WZ49"
FT   MOD_RES         117
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8JZQ2"
FT   VARIANT         74
FT                   /note="E -> A (in OPA12; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32548275"
FT                   /id="VAR_084603"
FT   VARIANT         306
FT                   /note="K -> E (in SPAX5; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32219868"
FT                   /id="VAR_084604"
FT   VARIANT         337
FT                   /note="G -> E (in OPA12; loss-of-function variant resulting
FT                   in aberrant OPA1 processing and mitochondrial
FT                   fragmentation)"
FT                   /evidence="ECO:0000269|PubMed:32548275,
FT                   ECO:0000269|PubMed:32600459"
FT                   /id="VAR_084605"
FT   VARIANT         337
FT                   /note="G -> R (in OPA12)"
FT                   /evidence="ECO:0000269|PubMed:32548275"
FT                   /id="VAR_084606"
FT   VARIANT         346
FT                   /note="L -> F (in OPA12; unknown pathological significance;
FT                   dbSNP:rs755893615)"
FT                   /evidence="ECO:0000269|PubMed:32219868"
FT                   /id="VAR_084607"
FT   VARIANT         376
FT                   /note="E -> K (in OPA12; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32548275"
FT                   /id="VAR_084608"
FT   VARIANT         377
FT                   /note="F -> S (in OPA12; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32219868"
FT                   /id="VAR_084609"
FT   VARIANT         407
FT                   /note="D -> G (in OPA12; unknown pathological significance;
FT                   decreased proteolytic function)"
FT                   /evidence="ECO:0000269|PubMed:32219868"
FT                   /id="VAR_084610"
FT   VARIANT         416
FT                   /note="R -> S (in OPA12; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32548275"
FT                   /id="VAR_084611"
FT   VARIANT         430
FT                   /note="T -> I (in OPA12; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32219868"
FT                   /id="VAR_084612"
FT   VARIANT         432
FT                   /note="N -> T (in SCA28; dbSNP:rs151344512)"
FT                   /evidence="ECO:0000269|PubMed:20208537"
FT                   /id="VAR_063544"
FT   VARIANT         462
FT                   /note="A -> V (in OPA12 and SPAX5; decreased proteolytic
FT                   function; dbSNP:rs912546325)"
FT                   /evidence="ECO:0000269|PubMed:32219868"
FT                   /id="VAR_084613"
FT   VARIANT         465
FT                   /note="R -> K (in OPA12; decreased proteolytic function)"
FT                   /evidence="ECO:0000269|PubMed:32219868"
FT                   /id="VAR_084614"
FT   VARIANT         468
FT                   /note="R -> C (in OPA12; decreased proteolytic function
FT                   resulting in impaired autocatalytic processing and impaired
FT                   proteolytic maturation of SPG7; does not affect the
FT                   interaction with SPG7; dbSNP:rs1020764190)"
FT                   /evidence="ECO:0000269|PubMed:26539208,
FT                   ECO:0000269|PubMed:29181157, ECO:0000269|PubMed:30252181"
FT                   /id="VAR_084615"
FT   VARIANT         514
FT                   /note="P -> L (in OPA12; decreased proteolytic function)"
FT                   /evidence="ECO:0000269|PubMed:32219868,
FT                   ECO:0000269|PubMed:32548275"
FT                   /id="VAR_084616"
FT   VARIANT         605
FT                   /note="Y -> C (in OPA12; unknown pathological significance;
FT                   dbSNP:rs773240455)"
FT                   /evidence="ECO:0000269|PubMed:32219868"
FT                   /id="VAR_084617"
FT   VARIANT         616
FT                   /note="Y -> C (in SPAX5; hypomorphic mutation; results in
FT                   impaired oligomerization with itself and SPG7; retains
FT                   ATPase and proteolytic activities; dbSNP:rs387906889)"
FT                   /evidence="ECO:0000269|PubMed:22022284"
FT                   /id="VAR_067330"
FT   VARIANT         620
FT                   /note="Q -> K (in SPAX5; impaired function shown in a yeast
FT                   complementation assay)"
FT                   /evidence="ECO:0000269|PubMed:32219868"
FT                   /id="VAR_084618"
FT   VARIANT         621
FT                   /note="L -> V (in SCA28; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:29053796"
FT                   /id="VAR_080736"
FT   VARIANT         644
FT                   /note="T -> S (in OPA12; unknown pathological significance;
FT                   dbSNP:rs1226952405)"
FT                   /evidence="ECO:0000269|PubMed:32548275"
FT                   /id="VAR_084619"
FT   VARIANT         654
FT                   /note="T -> I (in SCA28; dbSNP:rs151344513)"
FT                   /evidence="ECO:0000269|PubMed:20725928"
FT                   /id="VAR_064402"
FT   VARIANT         666
FT                   /note="M -> R (in SCA28; dbSNP:rs151344515)"
FT                   /evidence="ECO:0000269|PubMed:20725928"
FT                   /id="VAR_064403"
FT   VARIANT         666
FT                   /note="M -> T (in SCA28; dbSNP:rs151344515)"
FT                   /evidence="ECO:0000269|PubMed:20725928"
FT                   /id="VAR_064404"
FT   VARIANT         666
FT                   /note="M -> V (in SCA28; dbSNP:rs151344514)"
FT                   /evidence="ECO:0000269|PubMed:20725928,
FT                   ECO:0000269|PubMed:29053796"
FT                   /id="VAR_064405"
FT   VARIANT         671
FT                   /note="G -> E (in SCA28; dbSNP:rs151344518)"
FT                   /evidence="ECO:0000269|PubMed:20725928"
FT                   /id="VAR_064406"
FT   VARIANT         671
FT                   /note="G -> R (in SCA28; dbSNP:rs151344517)"
FT                   /evidence="ECO:0000269|PubMed:20725928"
FT                   /id="VAR_064407"
FT   VARIANT         689
FT                   /note="Y -> H (in SCA28; dbSNP:rs1598820860)"
FT                   /evidence="ECO:0000269|PubMed:24293060"
FT                   /id="VAR_075198"
FT   VARIANT         689
FT                   /note="Y -> N (in SCA28)"
FT                   /evidence="ECO:0000269|PubMed:26677414"
FT                   /id="VAR_075199"
FT   VARIANT         691
FT                   /note="E -> K (in SCA28; impaired function shown in a yeast
FT                   complementation assay; dbSNP:rs151344520)"
FT                   /evidence="ECO:0000269|PubMed:20208537,
FT                   ECO:0000269|PubMed:30252181"
FT                   /id="VAR_063545"
FT   VARIANT         694
FT                   /note="A -> E (in SCA28; dbSNP:rs151344521)"
FT                   /evidence="ECO:0000269|PubMed:20208537"
FT                   /id="VAR_063546"
FT   VARIANT         700
FT                   /note="E -> K (in SCA28; dbSNP:rs151344522)"
FT                   /evidence="ECO:0000269|PubMed:20354562"
FT                   /id="VAR_064408"
FT   VARIANT         702
FT                   /note="R -> Q (in SCA28; dbSNP:rs151344523)"
FT                   /evidence="ECO:0000269|PubMed:20208537"
FT                   /id="VAR_063547"
FT   MUTAGEN         575
FT                   /note="E->Q: Loss of autocatalytic processing. Impaired
FT                   proteolytic maturation of SPG7."
FT                   /evidence="ECO:0000269|PubMed:30252181"
FT   CONFLICT        74
FT                   /note="E -> G (in Ref. 1; CAB48398)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        633
FT                   /note="V -> A (in Ref. 1; CAB48398)"
FT                   /evidence="ECO:0000305"
FT   STRAND          165..169
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   HELIX           172..178
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   HELIX           180..182
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   STRAND          185..191
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   TURN            192..194
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   STRAND          195..200
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   TURN            202..204
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   STRAND          212..215
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   HELIX           219..232
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   TURN            237..239
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   STRAND          243..245
FT                   /evidence="ECO:0007829|PDB:2LNA"
FT   STRAND          297..299
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           307..309
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   TURN            315..317
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           318..328
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   TURN            332..337
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          344..347
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           356..364
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          369..373
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           374..376
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           385..398
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          403..408
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           409..411
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           422..439
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   TURN            440..442
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          443..445
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          450..452
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          457..459
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   TURN            461..464
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           480..490
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           504..512
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           518..525
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           527..532
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   TURN            533..536
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           543..552
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           565..584
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          585..588
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          591..595
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          605..608
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           618..628
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           630..637
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           647..661
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          668..670
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   STRAND          679..681
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           691..718
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           720..733
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           738..745
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   HELIX           756..759
FT                   /evidence="ECO:0007829|PDB:6NYY"
FT   TURN            761..763
FT                   /evidence="ECO:0007829|PDB:6NYY"
SQ   SEQUENCE   797 AA;  88584 MW;  EACBB7C5F2EE5E08 CRC64;
     MAHRCLRLWG RGGCWPRGLQ QLLVPGGVGP GEQPCLRTLY RFVTTQARAS RNSLLTDIIA
     AYQRFCSRPP KGFEKYFPNG KNGKKASEPK EVMGEKKESK PAATTRSSGG GGGGGGKRGG
     KKDDSHWWSR FQKGDIPWDD KDFRMFFLWT ALFWGGVMFY LLLKRSGREI TWKDFVNNYL
     SKGVVDRLEV VNKRFVRVTF TPGKTPVDGQ YVWFNIGSVD TFERNLETLQ QELGIEGENR
     VPVVYIAESD GSFLLSMLPT VLIIAFLLYT IRRGPAGIGR TGRGMGGLFS VGETTAKVLK
     DEIDVKFKDV AGCEEAKLEI MEFVNFLKNP KQYQDLGAKI PKGAILTGPP GTGKTLLAKA
     TAGEANVPFI TVSGSEFLEM FVGVGPARVR DLFALARKNA PCILFIDEID AVGRKRGRGN
     FGGQSEQENT LNQLLVEMDG FNTTTNVVIL AGTNRPDILD PALLRPGRFD RQIFIGPPDI
     KGRASIFKVH LRPLKLDSTL EKDKLARKLA SLTPGFSGAD VANVCNEAAL IAARHLSDSI
     NQKHFEQAIE RVIGGLEKKT QVLQPEEKKT VAYHEAGHAV AGWYLEHADP LLKVSIIPRG
     KGLGYAQYLP KEQYLYTKEQ LLDRMCMTLG GRVSEEIFFG RITTGAQDDL RKVTQSAYAQ
     IVQFGMNEKV GQISFDLPRQ GDMVLEKPYS EATARLIDDE VRILINDAYK RTVALLTEKK
     ADVEKVALLL LEKEVLDKND MVELLGPRPF AEKSTYEEFV EGTGSLDEDT SLPEGLKDWN
     KEREKEKEEP PGEKVAN
//
